1	SeqF	irst: Building equity access to a precise genetic diagnosis in critically ill newborns
2		
3	Tara I	Wenger, <sup>1,2</sup> Abbey Scott, <sup>2</sup> Lukas Kruidenier, <sup>2</sup> Megan Sikes, <sup>2</sup> Alexandra Keefe, <sup>1, 2</sup> Kati J.
4	Bucki	ngham, <sup>1</sup> Colby T. Marvin, <sup>1</sup> Kathryn M. Shively, <sup>1</sup> Tamara Bacus, <sup>1</sup> Olivia M. Sommerland, <sup>1</sup>
5	Kailyr	Anderson, <sup>1</sup> Heidi Gildersleeve, <sup>1</sup> Chayna J. Davis, <sup>1</sup> Jamie Love-Nichols, <sup>2</sup> Katherine E.
6	MacD	uffie, <sup>1,4</sup> Danny E. Miller, <sup>1-3,5</sup> Joon-Ho Yu, <sup>1,4,6</sup> Amy Snook, <sup>7</sup> Britt Johnson, <sup>7</sup> David L.
7	Veens	stra, <sup>8</sup> Julia Parish-Morris <sup>9</sup> , Kirsty McWalter, <sup>7</sup> Kyle Retterer, <sup>7,10</sup> Deborah Copenheaver, <sup>7</sup>
8	Betha	ny Friedman, <sup>7</sup> Jane Juusola, <sup>7</sup> Erin Ryan, <sup>7</sup> Renee Varga, <sup>7</sup> Dan Doherty, <sup>1-3</sup> Katrina
9	Dipple	e, <sup>1,2</sup> Jessica X. Chong, <sup>1,3</sup> Paul Kruszka, <sup>7</sup> Michael J. Bamshad, <sup>1-3</sup>
10		
11	1.	Department of Pediatrics, University of Washington, Seattle, WA, 98195, USA
12	2.	Seattle Children's Hospital, Seattle, WA, 98105, USA
13	3.	Brotman Bay Institute, Seattle, WA, 98195, USA
14	4.	Treuman Katz Center for Pediatric Bioethics and Palliative Care, Seattle Children's
15		Research Institute, 98121, Seattle WA, USA
16	5.	Department of Laboratory Medicine and Pathology, University of Washington, Seattle,
17		WA, 98195, USA
18	6.	Institute for Public Health Genetics, University of Washington, Seattle, WA, 98195, USA
19	7.	GeneDx, Gaithersburg, MD, 20877, USA
20	8.	Department of Pharmacy, University of Washington, Seattle, WA, 98195, USA
21	9.	Department of Biomedical and Health Informatics, Perelman School of Medicine,
22		Philadelphia, PA, 19146, USA
23	10.	Geisinger, Danville, PA, 17822, USA
24		
25		
26		

27

# 28 Corresponding author

- 29 Mike Bamshad, MD
- 30 Department of Pediatrics
- 31 University of Washington School of Medicine
- 32 Box 357371
- 33 1959 NE Pacific Street, HSB I607
- 34 Seattle, WA 98195
- 35 Correspondence: mbamshad@uw.edu
- 36
- 37 Word count:

## 38 Summary

39 Access to a precise genetic diagnosis (PrGD) in critically ill newborns is limited and inequitable 40 because complex inclusion criteria used to prioritize testing eligibility omits many patients at 41 high risk for a genetic condition. SegFirst-neo is a program to test whether a genotype-driven 42 workflow using simple, broad exclusion criteria to assess eligibility for rapid whole genome 43 sequencing (rWGS) increases access to a PrGD in critically ill newborns. All 408 newborns 44 admitted to a neonatal intensive care unit between January 2021 and February 2022 were 45 assessed and of 240 eligible infants, 126 were offered rWGS (i.e., intervention group [IG]) and 46 compared to 114 infants who received conventional care in parallel (i.e., conventional care group [CCG]). A PrGD was made in 62/126 (49.2%) IG neonates compared to 11/114 (9.7%) 47 CCG infants. The odds of receiving a PrGD was ~9 times greater in the IG vs. the CCG, and 48 49 this difference was maintained at 12 months follow up. Access to a PrGD in the IG versus CCG 50 differed significantly between infants identified as non-white (34/74, 45.9% vs. 6/29, 20.7%; 51 p=0.024) and Black (8/10, 80.0% vs. 0/4; p=0.015). Neonatologists were significantly less 52 successful at predicting a PrGD in non-white than non-Hispanic white patients. Use of a 53 standard workflow in the IG with a PrGD revealed that a PrGD would have been missed in 54 26/62 (42%) of infants. Use of simple, broad exclusion criteria that increases access to genetic 55 testing significantly increases access to a PrGD, improves access equity and results in fewer 56 missed diagnoses.

57

58

## 60 Introduction

61 Knowledge of the genetic basis of pediatric diseases has increased exponentially over 62 the past decade and genetic variation plays a role in virtually all pediatric conditions. New 63 technologies to rapidly and inexpensively interrogate human genomes, powerful computational 64 approaches to identify disease-causing (i.e., pathogenic) variants, and high-throughput 65 functional assays to facilitate development of precision therapeutics, have converged to create an unprecedented opportunity to capitalize on this information and use genomics to 66 67 revolutionize pediatric healthcare. Indeed, the widespread application of genomics (e.g., exome sequencing / whole genome sequencing [ES / WGS]) in clinical genetics has had a major 68 impact on the ability to make a precise genetic diagnosis (PrGD) in patients with rare conditions 69 (RCs).<sup>1,2</sup> Use of ES / WGS increases diagnostic rates, enables faster diagnosis, reduces costs, 70 71 and improves both family and provider satisfaction while a delayed or absent PrGD can result in both missed or inappropriate interventions.<sup>3–21</sup> Nevertheless, integration of ES / WGS into most 72 pediatric clinical programs and specialty services has been modest at best.<sup>22-29</sup> 73 74 Rapid ES / WGS is transforming diagnosis and care of RCs in critically ill newborns. 75 Evidence from more than forty studies that collectively have evaluated >3.500 families is compelling.<sup>3–13,15–21,26,29–54</sup> Yet, the impact of the widespread use of rapid ES / WGS has been 76 77 blunted, to date, by the lack of availability of effective service-delivery models that support 78 scalability (i.e., widespread adoption in neonatal intensive care units [NICUs], offering testing to all infants with a high prior risk for a genetic condition, etc.) limiting equitable access to a PrGD 79 (i.e., offering a genetic test and receipt of a test result that explains a patient's clinical 80 findings).<sup>55–57</sup> Indeed, most children in the United States who could benefit from a PrGD aren't 81 offered advanced genetic testing since the availability of genetic testing is highly dependent 82 upon institution, geography, and social class.<sup>6</sup> Another challenge is that non-specific 83 84 presentations of RCs are common, and thus suspicion of a RC as a prerequisite to request 85 genetic testing excludes many, if not most, individuals with a RC from access to testing.

Moreover, the ability to offer testing is most compromised in communities that have traditionally been underserved and disproportionately represented by families that identify as Black, Indigenous, People Of Color and / or living in rural areas.<sup>58,59</sup> This disparity is compounded by structural racism resulting in inequities in NICU care for underrepresented minorities. These inequities are driven in part by a lower likelihood of admission to a high quality medical center and differences in care compared to white infants admitted to the same NICUs.<sup>60–66</sup> This is a major gap in healthcare.

93 SegFirst is a research initiative established to develop and test innovative genotype-94 driven service delivery models in pediatric care settings that serve diverse communities with varied levels of infrastructure for providing clinical genetic services. It currently includes three 95 arms: SegFirst-Ddi, focused on children under three years of age newly found by their parents 96 97 or primary care providers to have atypical development; SeqFirst-All Kids Included, aimed at 98 supporting access to a PrGD in underserved communities; and SegFirst-neo, a project to 99 develop and test approaches to center equity for a PrGD at the initial point of care of infants with 100 a critical illness. Each of these arms also represent an opportunity to develop and deploy 101 complementary technological strategies to support provider readiness (e.g., telemedicine 102 consults, virtual consenting, self-guided return of results, etc.).

Herein we present the results of Phase 1 of SeqFirst-neo in which we implemented a genotype-driven workflow using simple, broad exclusion criteria to assess eligibility for rapid whole genome sequencing (rWGS) and tested its impact on several outcomes including access to a PrGD, diagnostic yield, and changes in clinical management in critically ill newborns. We also compared these outcomes among groups delimited by self or provider assigned population descriptors including race to test whether access to a PrGD was equitable.

109

#### 110 Subject, material, and methods

111 Patient selection and enrollment

112 This study was reviewed and approved by the University of Washington IRB # 113 STUDY00008810 and consent was obtained for each participant. Exclusion criteria were 114 developed by a multidisciplinary team of care-providers and researchers including clinical 115 genetics, genetic counseling, and neonatology. Exclusion criteria included a corrected age > 6 116 months or clinical findings fully explained by physical trauma, infection, or complications of 117 prematurity. Infants with clinical findings initially considered fully explained by physical trauma, 118 infection, or complications of prematurity who developed, as judged by a neonatologist, an 119 atypical clinical course (e.g., excessive bleeding) during their hospitalization were offered 120 enrollment. Infants with a pre-existing PrGD via prenatal genetic testing or postnatal testing at 121 their birth hospital were also excluded. Eligibility did not require sample collection from any 122 biological parents.

123 From January 2021 to February 2022, the admission notes of each infant admitted to the 124 NICU at Seattle Children's Hospital (SCH), a tertiary pediatric hospital located in an urban 125 setting, were briefly (i.e., 2-3 minutes) assessed remotely each day by a clinical geneticist 126 (T.W., K.D., M.B.) to determine eligibility (Figure 1). This assessment was then confirmed with 127 the neonatologist on service. Eligible families were approached by a research team member, 128 either a genetic counselor or clinical geneticist, to assess parental interest in enrollment. 129 Interpreter services were used as needed. Infants enrolled were assigned to the intervention 130 group (IG). Conventional clinical care and testing, including genetic testing, continued in parallel 131 for each infant enrolled in SeqFirst without restriction on tests ordered. Families were given the 132 option to receive secondary findings. If no clinical genetics consult had been obtained through conventional clinical care, reporting of a variant of unknown significance, likely pathogenic, 133 134 pathogenic, or secondary result triggered consultation.

Patients who were eligible but not enrolled (e.g., families not available for consent or declined to participate) were assigned to a conventional care group (CCG). Standard clinical care and testing, including genetic testing, continued for each infant in the CCG. The SeqFirst

and CCG were well-matched for gestational age at birth, age at admission, sex assigned at
 birth, admitting diagnosis, and parent- or provider-assigned racial construct (PPARC) (Table 1).

140

141 Rapid whole genome sequencing

142 Whole blood was collected from the proband, parents, and, if necessary, additional 143 family members (e.g., siblings). rWGS was performed using a CLIA-certified, commercially 144 available clinical test (GenomeXpress) offered by GeneDx. In brief, PCR-free whole genome 145 sequencing libraries were prepared using Illumina DNA PCR-Free Prep, Tagmentation kit 146 following the manufacturer's protocol (Illumina Inc.). Massively parallel (NextGen) sequencing was performed on an Illumina platform. Average mean sequencing coverage was at least 40x 147 across the genome, with a minimum threshold of 30x for any proband sample. Bi-directional 148 149 sequence reads were assembled and aligned using Dragen to reference sequences based on 150 NCBI RefSeg transcripts and human genome build GRCh37/UCSC hg19. Using a custom-151 developed analysis tool, data were filtered and analyzed to identify sequence variants, repeat 152 expansions in FMR1 and DMPK, homozygous loss of SMN1 exon 8, and most deletions and 153 duplications greater than 1 kb in size. PCR-free whole genome sequencing libraries were 154 prepared using Illumina DNA PCR-Free Prep, Tagmentation kit following the manufacturer's 155 protocol (Illumina Inc.). Massively parallel (NextGen) sequencing was performed on an Illumina 156 platform. Average mean sequencing coverage was at least 40x across the genome, with a 157 minimum threshold of 30x for any proband sample. Bi-directional sequence reads were 158 assembled and aligned using Dragen to reference sequences based on NCBI RefSeq 159 transcripts and human genome build GRCh37/UCSC hg19. Using a custom-developed analysis 160 tool, data were filtered and analyzed to identify sequence variants, repeat expansions in FMR1 161 and DMPK, homozygous loss of SMN1 exon 8, and most deletions and duplications greater 162 than 1 kb in size. Additional sequencing technology and variant interpretation protocol has been previously described<sup>67</sup>. The general assertion criteria for variant classification are publicly 163

## available on the GeneDx ClinVar submission page

(https://www.ncbi.nlm.nih.gov/clinvar/docs/review\_status/#ac). All reported variants were 165 166 confirmed by an orthogonal method in the proband and parents, if available. A result including nuclear pathogenic and/or likely pathogenic variants potentially explaining a patient's clinical 167 168 findings was verbally communicated to the research team within seven calendar days and 169 written results within fourteen days. 170 Each reported variant was interpreted by the research team including at least two clinical 171 geneticists and a genetic counselor and each reported variant(s)/gene(s) was assigned to one 172 of five categories: clinical findings explained, clinical findings likely explained, clinical findings partially explained (i.e., a variant(s) explains at least one but not all clinical findings), clinical 173 174 findings not explained, secondary finding unrelated to clinical findings. Assignments were made 175 based on a combination of clinical judgement of phenotype specificity and similarity to 176 previously reported gene-disease phenotypes, use of the ClinGen gene-disease validity 177 framework, and use of the ACMG/AMP sequence variant classification (SVC) and 178 ACMG/ClinGen CNV classification guidelines (plus soon to be released 179 ACMG/AMP/CAP/ClinGen v4 SVC guidelines). We required at least a moderate level of gene-180 disease validity for a gene to be potentially considered explanatory and at least near-moderate 181 for likely explained. A PrGD was assigned to an infant if they had at least one variant 182 categorized as clinical findings explained, likely explained, or partially explained. 183 Return of results and collection of clinical data 184 Upon verbal receipt of a result, the research team communicated the result to the clinical 185 team. Results that were considered explanatory (i.e., explained, likely explained, or partially 186

187 explained) and secondary results were returned to the family by the clinical genetics

188 consultants. Results that were non-explanatory were returned to the family by the research

189 team.

Information about the clinical course of each infant in the IG was collected from the electronic medical record (EMR). Additional information was collected via electronic surveys administered to parents/guardians upon completion of consent (pregnancy, birth, and family history), after results disclosure (impact of results returned), and at 6, 12, and 18 months (developmental milestones and healthcare utilization) after enrollment. For CCG infants, clinical data including gestational age at birth, age at admission, diagnoses at admission, and PrGD were collected from the EMR.

Access to a PrGD was assessed upon receipt of results, and at 3 and 15 months after enrollment. These latter two time points were selected to allow for completion of additional testing (e.g., orthogonal validation of results, evaluation for somatic mosaicism, etc.) and clinical evaluations, both of which were used to assist adjudication of variants found via rWGS and identify variants not detected by rWGS. Changes in management were defined as actions taken as a result of a PrGD including additional laboratory testing, imaging, consultations, procedures, and changes in medical treatment.

Race and ethnicity information were collected by review of family history obtained by a genetic counselor or clinical geneticist, and from race and ethnicity terms reported in the EMR. Information collected by a provider was prioritized over that obtained from the EMR. Each individual was assigned by the research team to one of six PPARC: Asian, Black, Hispanic, Native American, non-Hispanic white and non-white multi-racial (NWMR).

209

210 Outcomes and Statistical analysis

Primary outcomes assessed were: 1) access to a PrGD defined as the percentage of patients eligible for testing who received a PrGD; 2) diagnostic yield defined in the IG as the percentage of patients tested with a variant identified by rWGS that likely explained, explained, or partially explained the clinical findings of a patient and in the CCG as a variant identified by any genetic testing that likely explained, explained, or partially explained the clinical findings of a

patient; 3) access to a PrGD and diagnostic yield among PPARC groups; and 4) PrGD missed
in the IG defined as families with a PrGD in whom genetic testing was not offered as part of
conventional care. In the IG, access to a PrGD and diagnostic yield are identical metrics as all
patients were tested.

The primary comparison between rate of PrGD diagnosis in the IG vs. CCG was made using a generalized linear model (logistic regression), with  $\chi^2$  or Fisher's exact test applied to smaller subsample comparisons. Fisher's exact test was used when greater than 20% of cells had fewer than five individuals. Regressions were conducted in R version 4.4.1<sup>68</sup>, with condition coded as CCG=0 and IG=1. A p-value of 0.05 or less was deemed statistically significant.

225

## 226 **Results**

227 From January 2021 to February 2022, 408 infants were admitted to the NICU (Figure 1). A total of 168 patients were ineligible (Supplementary Table 1) because their clinical findings 228 229 were explained by birth trauma (n=64), prematurity (n=47), infection (n=36), a pre-existing PrGD 230 (n=15) and "other" reasons including observation for a condition not identified (n=6). Two 231 hundred forty infants were eligible to participate. Thirty-one infants were discharged, transferred 232 from the NICU, or died before their families were available for eligibility screening and were 233 therefore considered "missed." Two hundred nine families were screened, and 126 (60%) 234 enrolled in the IG. Most enrolled patients (n=89, 71%) had either multiple congenital anomalies 235 (n=56, 44%) or an anomaly of a single organ / body part (n=33, 26%). Twelve infants had either abnormal laboratory tests (n=10, 8%) or hematological abnormalities (n=2, 2%); 9 (7%) had 236 237 seizures, 6 (5%) had single or multi-organ failure, 3 (2%) had strokes, and 7 (6%) had other 238 unclassified admission diagnoses (e.g., congenital ichthyosis, meconium ileus, vocal cord 239 paresis, etc. [Supplementary Table 2]).

A total of 83 families declined to participate (Supplementary Table 3). Thirty-two parents did not respond to requests for interview. The remaining families cited being overwhelmed

242 (n=26), concerns that testing was unnecessary (n=13), discomfort with research (n=7),

concerns over privacy (n=3), or concerns about phlebotomy (n=2). Infants who were eligible but

<sup>244</sup> "missed" (n=31) or whose parents declined to participate (n=83) were assigned to the CCG

245 (n=114).

246 Eighty-five infants had one or more variants or events reported by GeneDx that 247 disrupted 120 genes, genomic regions or the mitochondrial genome (Figure 2). No variants 248 were reported in 41 infants (Figure 2). Clinical interpretation of these variants and events led to 249 a rapid PrGD in a total of 62/126 (49%) infants in the IG in the first 90 days post enrollment 250 (Table 2, Figure 3). Most infants were reported to have variant(s) that explained (n=37; 29%) or likely explained (n=21: 17%) their clinical findings (Figure 2). Clinical findings were partially 251 252 explained in 4 (3%) infants. No PrGD was made in 64/126 infants (51%) including 7 (6%) who 253 received only secondary findings and 57 (45%) in whom no explanatory variants were identified. 254 In the CCG, a PrGD was made in 11/114 (10%) infants within their first 90 days of 255 hospitalization, significantly fewer (49% vs. 10%, p<0.00001) than in the IG (Figure 3). This 256 difference was sustained over the ensuing 12 months, 63/126 or 50%, in the IG compared to 257 12/114 or 11% in the CCG (p<0.00001). This difference reflected differences in access to genetic testing as only a subset (n=46) of infants in the CCG underwent clinical genetic testing, 258 259 and even fewer (n=7) underwent ES in the first fifteen months of life (Supplementary Table 4). 260 But even among patients who received any type of genetic testing, the difference in diagnostic 261 yield in PrGD between the IG and the CCG was significant at 90 days (62/126, 49% vs. 11/45, 262 24%; 0.0039) and remained significant (63/126, 50% vs. 12/46, 26%; p=0.0087). Logistic regression revealed a significant effect of use of exclusion criteria in the IG vs. 263 264 CCG on the likelihood of receiving a PrGD ( $\beta = 2.07, 95\%$  CI = 1.40-2.80, Z=5.84, p<.0001). 265 This effect translates to an odds ratio (OR) of 7.92, meaning that infants in the IG were nearly 8

times more likely to receive a PrGD than infants in the CCG group, and the odds of receiving a

267 PrGD increased by 692% for infants in the IG vs. CCG group. This effect remained significant

after controlling for infant sex and race/ethnicity in the model ( $\beta$  = 2.21, 95% CI = 1.53-2.98, Z=6.02, *p*<.0001, OR=9.16).

270 Of 126 patients in the IG, the diagnostic yield varied by phenotypic categorial group 271 (Table 3, Figure 4A) from 33% in those with isolated structural anomalies to 70% in infants with 272 laboratory abnormalities and infants with clinical findings not easily categorized (71%) 273 (Supplementary Table 5). The diagnostic yields in infants with multiple congenital anomalies 274 (MCA; 54%), whether with (57%) or without (50%) congenital heart defects (CHD), and seizures 275 (56%) were similar. A PrGD was made in both patients with hematological abnormalities but 276 none of the 3 patients with stroke. A total of 68 conditions were identified in the 63 infants who received a PrGD including 59 infants with a single condition, 3 infants with two conditions, and 277 278 one infant with three conditions. Inherited or de novo autosomal dominant events were 279 responsible for 32 of 68 (47%) conditions found in 31 infants. Twenty-two autosomal recessive 280 conditions were identified in 21 infants and 6 X-linked conditions were identified in 6 infants. 281 Eleven chromosomal abnormalities including aneuploidy, uniparental disomy, microdeletions, or 282 duplications were observed in 11 infants. Four infants had mitochondrial disorders, two as a 283 result of mtDNA mutations and two with autosomal recessive conditions (Supplementary Table 284 6).

The number of infants with CHDs in the IG is notably lower than is typical of infants 285 286 admitted to a NICU as most newborns admitted to SCH with CHDs are instead admitted to a Cardiac Intensive Care Unit (CICU). For this reason, from August 2021 to December 2021, we 287 288 applied the same eligibility criteria and assessment workflow to infants admitted to the CICU until a sample size of 25 families was reached. A total of 52 infants were assessed, 42 of whom 289 290 were eligible. Forty-one families were interviewed, and 25 (61%) enrolled in SeqFirst. Most 291 enrolled patients (n=15, 60%) had an isolated CHD (Supplementary Table 7). Fourteen of these 292 were simplex families and one infant had a family history of dominantly inherited CHD. Nine 293 infants had CHD as one of multiple congenital anomalies, and one infant was admitted with

supraventricular tachycardia. A PrGD was made in a total of 8/25 (32%) infants in the CICU
group, 3 /15 (20%) of the infants with isolated CHD, and 5/9 (56%) of the infants with MCA.

296

297 Stratification by patient or provider assigned racial construct (PPARC)

298

299 Access to a PrGD among PPARC groups in the IG in the first 90 days of hospitalization 300 ranged between 20% (1/5; Native American) and 80% (8/10; Black) but none of these 301 differences were statistically significant (Table 2, Figure 4B). Access to a PrGD was not statistically different among PPARC groups 12 months later (p=0.1107). Across PPARC groups 302 in the CCG, a PrGD was made in 5 families that identified as non-Hispanic white, 4 that 303 identified as Asian and 2 that identified as Hispanic in the first 90 days. A PrGD was not made in 304 305 any family that identified as Black, multi-racial, or Native American. A PrGD was made in only 306 one additional infant, (i.e., 12 / 114 families instead of 11 / 114 families) 12 months later. The 307 small number of PrGD in CCG families precluded a robust test of statistical significance of 308 differences across PPARC groups at either assessment point. In both the IG and the CCG, 309 collapsing PPARC assignments and comparing non-Hispanic whites to non-whites or comparing 310 non-Hispanic whites to Black+1P where families with at least one parent who identified as Black 311 were categorized as Black instead of multi-racial did not reveal statistically significant 312 differences in access to a PrGD.

Access to a PrGD in PPARC groups in the IG compared to the CCG at 90 days differed significantly between non-Hispanic white (28/52, 54% vs. 5/48, 10%; p<0.00001), non-white (34/74, 46% vs. 6/59, 10%; p<0.00001), Black (8/10, 80% vs. 0/12; p=0.00001) and Black+1P (11/17, 65% vs. 0/17; p=0.0001) groups. Access to a PrGD did not differ significantly between Asian (p=0.1043), Hispanic (p=0.0764), Native American (p=1.0), or multi-racial (p=0.1137) PPARC groups in the IG compared to the CCG groups. These differences in access to a PrGD between the IG and CCG result in part from differences in access to genetic testing, which

differed significantly between the groups. Accordingly, we repeated the analysis but included only CCG infants who were tested. The difference in access to a PrGD in the IG versus CCG non-Hispanic white group was no longer statistically significant (p < 0.1) whereas the difference in access to a PrGD in the IG versus CCG remained statistically significant between non-white (34/74, 46% vs. 6/29, 21%; p=0.024), Black+1P (11/17, 65% vs. 0/8; p=0.003), and Black (8/10, 80% vs. 0/4; p=0.015) groups.

326

327 Yield of precise genetic diagnoses in newborns not suspected of having a genetic condition

328

For participants in the IG who had a PrGD made in the first 90 days, we compared their 329 330 outcome to that from testing provided in parallel per a standard clinical workflow. This revealed 331 use of a standard workflow for ascertainment and testing would have been missed a PrGD in 332 26/62 (42%) of these infants (Supplementary Table 8, Supplementary Figure 1). Nearly one 333 quarter (15/62; 24%) of the infants who received a PrGD in the IG in the first 90 days did not 334 have documented suspicion of a genetic condition in their EMR and therefore were not offered 335 clinical genetics consultation or genetic testing as part of their conventional care. All but one 336 (14/15) of these infants were diagnosed with genetic conditions that do not have recognizable 337 physical features, and most of these infants were described as having an unexpected response 338 to therapies or severity of illness disproportionate to what was expected based upon provisional clinical diagnosis. Moreover, 10/15 (67%) of these infants were identified as a PPARC other 339 340 than non-Hispanic white. An additional 11/26 infants did not receive a PrGD despite clinical genetics consultation and targeted genetic testing (n=9) or because of lack of access to testing 341 due to demise shortly after admission (n=2). Moreover, twice as many of these infants (n=18)342 343 identified with a PPARC other than non-Hispanic white compared to those that identified as 344 white (n=8).

345 We sought to assess the ability of neonatologists to predict which patients would receive 346 a PrGD from the information available to them. We defined successful prediction of PrGD status 347 as requesting a genetics consult in a patient who was later found to have a PrGD and not 348 requesting a genetics consult in a patient who did not receive a PrGD. Overall, neonatologists requested a consult in 76% of patients with a PrGD (i.e. recall) and did not request a consult in 349 350 56% of patients without a PrGD (i.e. precision). However, we hypothesized that there were 351 differences in their ability to predict a PrGD in non-white vs non-Hispanic white patients (Figure 352 5). We used a logistic model to assess the effects of PPARC, referral for a consult, and the 353 interaction between these variables on prediction of a PrGD. Although the impact of neither PPARC nor whether a consult alone was significant, there was a significant interaction term 354 355 (coef=1.8, p=0.034). This indicates non-Hispanic white infants referred for genetics consultation 356 were 6.1 times more likely to receive a PrGD than non-white infants referred for a genetics 357 consultation. Conversely, non-white infants who were not referred for a genetics consult were 358 2.4 times more likely to receive a PrGD than white infants who also were not referred. To 359 confirm these findings, we used an alternative analysis approach assessing differences in 360 precision (not referring patients who did not later receive a PrGD) and recall (referring patients 361 who later did receive a PrGD). We observed relatively high precision (75%) and recall (86%) for 362 non-Hispanic white patients while both precision and recall were markedly lower (55% and 68%, 363 respectively) for non-white patients, yielding a composite F1 score of 0.61 for non-white patients vs. 0.8 for non-Hispanic white patients. We performed a bootstrapping analysis with 10,000 364 365 replicates to assess the significance of the differences in F1 score (p=0.013), precision (p=0.033), and recall (0.04) between non-white and non-Hispanic white PPARC groups. 366 Both analyses show that neonatologists were significantly less successful at predicting a 367 368 potential PrGD in non-white patients compared to non-Hispanic white patients. That is they

369 missed referring for genetics consult disproportionately more often in non-white patients who

would eventually receive a PrGD and simultaneously referred more non-white patients for aconsult who did not go on to receive a PrGD.

372

373 Impact of a precise genetic diagnosis on changes in management

374

375 Using simple exclusion criteria to assess eligibility for testing and use of rWGS as a first-376 tier test revealed a high proportion of individuals across the IG with results that impacted their 377 clinical care. These impacts fell in one or more of eight changes in management (COM) options 378 (Figure 6). At 90 days after enrollment, access to a PrGD in the IG informed COM in 60 of 62 (97%) patients (Figure 5, Supplementary Table 9). Of the 60 families, anticipatory guidance was 379 380 provided to 53 (88%) and 51 (85%) received recurrence risk counseling. Fifty-two families (87%) 381 had at least one COM other than guidance or counseling. Of these families, the most common 382 management change (38/52; 73%) was request for consultation from additional specialists for 383 further evaluations, typically to facilitate medical decision-making, or consideration of diagnostic 384 imaging procedures. In 16 (31%) of these patients, a PrGD resulted in request for additional 385 laboratory testing, and a PrGD brought about a change in therapeutics in 10 patients (19%). In 386 15 of these 52 families (29%) with a change in management, a PrGD in their newborn had 387 health-related implications for other family members leading to additional genetic testing and/or 388 referrals for medical care (e.g. initiation of screening for hereditary hemorrhagic telangiectasia in 389 a parent). Among 22 families of infants with a PrGD of a condition associated with early 390 mortality, a PrGD contributed to a change in goals of care including a shift to palliative support 391 in 5 (23%) infants.

A total of 28 unique combinations of COM were observed, the most common of which included guidance, counseling, and request for consultation (Figure 5). We then tested whether, given a PrGD, a participant's downstream care was impacted by comparing differences in the total number of COM and for any specific COM between non-Hispanic white and non-white PPARC

groups and between non-Hispanic white versus Black+1P groups. None of the comparisons reached
statistical significance (Wilcoxon rank sum test p > 0.2 for all comparisons). There was also no
significant difference in total number of COM or any individual COM upon excluding anticipatory
guidance and recurrence risk counseling.

400

## 401 Discussion

402 We tested the impact of a genotype-driven workflow using simple, broad exclusion 403 criteria to identify infants with critical illness who might benefit from rWGS as a first-line test. 404 using access to a PrGD, diagnostic yield, access to a PrGD and diagnostic yield among PPARC 405 groups, and missed PrGD in families not offered clinical genetic testing, as primary outcome 406 measures. Use of this workflow significantly increased access to a PrGD and diagnostic yield in 407 newborns admitted to the NICU and this increase was sustained over the ensuing year. Indeed, 408 only 14% of infants who received conventional care were even offered ES by the age of fifteen 409 months, suggesting that access to a PrGD further worsens upon discharge from the NICU, and 410 only about half of these infants (6.1%) underwent ES because of declination or barriers to 411 testing in the outpatient setting (e.g., insurance denials or requirement for additional clinical 412 evaluations). In other words, not using exclusion criteria to determine eligibility for rWGS to 413 infants in the NICU resulted in both an immediate and sustained loss of access to a PrGD and 414 thereby multiple missed opportunities for intervention.

Significantly more infants identified as non-white or Black received a PrGD in the IG compared to the CCG, whereas access to a PrGD was comparable across all PPARC groups in the IG. In other words, access to a PrGD was equitable in the IG as a whole and across all PPARC groups compared to the CCG. This is due both to lack of access to genetic testing for infants in the CCG and that when testing was ordered for infants in the CCG, tests with lower diagnostic rates than rWGS were requested, particularly in non-white patients. Achieving equity in access to a PrGD will necessitate removing the many barriers that lead to disparities in

underserved populations. Our results suggest that access to testing is a significant barrier in the
 NICU and that equitable access to a PrGD can be achieved by using simple exclusion criteria
 rather than conventional patient selection criteria as the basis for offering testing.

425 By comparing rWGS eligibility using simple, broad exclusion to typical inclusion criteria, 426 we observed that the conventional workflow limits access to genetic testing and would have 427 missed the opportunity to make a PrGD in 42% of infants with a PrGD in the IG, despite a 428 substantial infrastructure for providing inpatient clinical genetics services. Most of these infants 429 were non-dysmorphic with common clinical findings. Non-specific presentations of genetic 430 diseases are common in the NICU, and some studies have suggested that requiring a suspicion of a genetic condition as a prerequisite to genetic testing will not only delay ordering testing but 431 432 will miss up to half of all genetic conditions leading to NICU admission. With approximately 800 433 NICUs in the U.S. (most of which do not have access to clinical geneticists, genetic counselors 434 or ES/WGS), and about 400,000 newborn admissions annually, tens of thousands of newborns 435 admitted to NICUs likely have genetic conditions that are missed due to lack of access to genetic testing, much less access to a PrGD.<sup>69</sup> Our approach mitigated disparities in access to 436 437 genetic testing, particularly in non-whites.

438 A primary outcome metric used to assess the utility of ES / WGS, particularly in critical 439 care settings, is diagnostic yield. We anticipated that by using a simplified clinical workflow that 440 based eligibility on excluding infants whose clinical findings were fully explained by indications for NICU admission unlikely due to a genetic variant(s) with a large effect (i.e., prematurity, 441 442 trauma, or infection), the diagnostic yield in the IG would be low in general and lower than that of standard care provided in parallel. Instead, the diagnostic yield in the IG (50%) was higher 443 444 than in the conventional care group (26%). This is higher than the average diagnostic yield 445 across more than thirty studies evaluating the use of rapid ES / WGS in pediatric critical care 446 settings and accounted for largely by the PrGD made in infants who a neonatologist did not 447 suspect to have a genetic condition based on clinical findings.

448 Use of diagnostic rate as a proxy for the value of genomic testing has, in our opinion, the 449 potential to be misleading as a primary outcome measure. Diagnostic rates vary widely, often by 450 several fold, across different cohorts, conditions, and clinical contexts, each of which can be defined in ways to maximize the pre-test probability of a PrGD and therefore diagnostic vield.<sup>70</sup> 451 452 But maximizing pre-test probability of a PrGD can adversely impact access to a PrGD. For 453 example, the combination of subjectivity in case selection and the constraint of expert 454 availability has motivated development and validation of objective criteria to stratify families for 455 ES / WGS to maximize diagnostic rate. Such criteria are typically complex and challenging to 456 navigate even for expert clinical geneticists. Moreover, use of such criteria can be laborintensive, confusing, and intimidating for non-genetics providers (e.g., neonatologists). As a 457 458 result of these complex clinical workflows and lack of support for non-genetics providers, 459 critically ill infants who could benefit from genetic testing may often not be offered testing due to 460 ineligibility against these criteria or never having been evaluated for eligibility in the first place. 461 Simple exclusion criteria have the potential to improve access to a PrGD by offering a straightforward, objective workflow for clinicians. 462 463 Limitations of this study include that it was performed at a single site of care with 464 potential differences in access to admission to the NICU and that its duration was limited to just 465 a year. It is possible that differences in access to genetic testing and a PrGD between the IG

and CCG are partly due to a selection bias resulting in more families in the CCG who were less

468 could not be offered. However, of the 114 families enrolled in the CCG 90% (46/51) who were

interested in testing or a PrGD, and / or a higher number of deaths in the CCG such that testing

469 offered genetic testing consented to testing and while there were 10 deaths (9% of the cohort) in

the CCG, 15 infants (12%) in the IG died in the first year of life. Differences in the presenting

471 clinical findings between the IG and CCG might have also led to differences in access to testing

and / or diagnostic yield. However, the percentage of patients with multiple congenital

467

473 anomalies, isolated congenital anomalies, abnormal lab values, and seizure disorders was

similar in each cohort. While survey and EMR data were available for the IG so that, for
example, families could be directly questioned about the impact of a PrGD on clinical care, for
the CCG, data were available only from the EMR. Lastly, the sample sizes of individual PPARC
groups were small, necessitating labeling patients into broad categories such as non-Hispanic,
white and non-white. This limits assessment of impact to a high, rather than granular, level
thereby impeding identification of potential barriers to testing.

480

#### 481 Conclusions

482 Our results suggest that use of a simple workflow based on exclusion of only infants with clinical findings fully explained by prematurity, infection, or trauma to assess eligibility for rWGS 483 coupled with support of provider readiness improves access to a PrGD and more equitable 484 485 access to a PrGD. Major limitations of conventional workflows include dependence on use of 486 complex stratification algorithms to maximize diagnostic rates and stepwise testing to minimize 487 cost that alone, much less in combination, are challenging to operationalize and result in missed 488 opportunities to make a PrGD, particularly in non-white infants. Collectively, our results 489 demonstrate clear opportunities exist to improve equitable access to a PrGD in critically ill 490 newborns and are a step toward establishing a practice to increase equity in the use of 491 genomics in the critical care of infants and in Pediatrics in general.

492

#### 493 Acknowledgements

We thank the families for their participation and support. We thank the faculty and staff of the
SCH NICU and the CICU. Financial support was provided by grants from GeneDx, the BrotmanBaty Institute, and University of Washington Center for Rare Disease Research (UW-CRDR)
with additional contributions from NHGRI grants U01 HG011744, UM1 HG006493,

and U24 HG011746. The content is solely the responsibility of the authors and does not

499 necessarily represent the official views of the National Institutes of Health.

500

## 501 Declaration of Interests

- 502 M. Bamshad is on the Scientific Advisory Board of GeneDx, and has research agreements with
- 503 GeneDx, Illumina, Inc., and PacBio, Inc. All GeneDx authors are/were employed by and may own
- stock in GeneDx, Inc. D.L. Veenstra has served as a consultant to Illumina, Inc. D.E. Miller is
- <sup>505</sup> engaged in a research agreement with Oxford Nanopore Technologies (ONT). ONT has paid for
- 506 D.E. Miller to travel to speak on their behalf. D.E. Miller holds stock options in MyOme. Other
- 507 authors declare no competing interests.

508

#### 509 Data and code availability

- 510 All data needed to evaluate the conclusions in the paper are present in the paper and/or the
- 511 supplemental information. The rWGS data will be deposited in NHGRI's Analysis Visualization
- and Informatics Lab-space (AnVIL) (accession number phs003047, "internal\_project\_id"
- 513 contains seqfirst-neo). All other data are available upon request and if consistent with the
- 514 informed consent of study participants.
- 515
- 516
- 517
- 518
- 519
- 520
- 521
- 522
- 523

## 524 **References**

- Bamshad MJ, Nickerson DA, Chong JX. Mendelian Gene Discovery: Fast and Furious with No End in
   Sight. *Am J Hum Genet*. 2019;105(3):448-455. doi:10.1016/j.ajhg.2019.07.011
- Chong JX, Buckingham KJ, Jhangiani SN, et al. The Genetic Basis of Mendelian Phenotypes:
   Discoveries, Challenges, and Opportunities. *Am J Hum Genet*. 2015;97(2):199-215.
- 529 doi:10.1016/j.ajhg.2015.06.009
- Cakici JA, Dimmock DP, Caylor SA, et al. A Prospective Study of Parental Perceptions of Rapid Whole Genome and -Exome Sequencing among Seriously III Infants. *Am J Hum Genet*. 2020;107(5):953-962.
   doi:10.1016/j.ajhg.2020.10.004
- 4. Kingsmore SF, Cakici JA, Clark MM, et al. A Randomized, Controlled Trial of the Analytic and
  Diagnostic Performance of Singleton and Trio, Rapid Genome and Exome Sequencing in III Infants. Am
  J Hum Genet. 2019;105(4):719-733. doi:10.1016/j.ajhg.2019.08.009
- 5. Dimmock DP, Clark MM, Gaughran M, et al. An RCT of Rapid Genomic Sequencing among Seriously III
   Infants Results in High Clinical Utility, Changes in Management, and Low Perceived Harm. *Am J Hum Genet*. 2020;107(5):942-952. doi:10.1016/j.ajhg.2020.10.003
- 6. Wu B, Kang W, Wang Y, et al. Application of Full-Spectrum Rapid Clinical Genome Sequencing
  Improves Diagnostic Rate and Clinical Outcomes in Critically III Infants in the China Neonatal
  Genomes Project. *Crit Care Med*. 2021;49(10):1674-1683. doi:10.1097/CCM.00000000005052
- Ouyang X, Zhang Y, Zhang L, et al. Clinical Utility of Rapid Exome Sequencing Combined With
   Mitochondrial DNA Sequencing in Critically III Pediatric Patients With Suspected Genetic Disorders.
   *Front Genet*. 2021;12:725259. doi:10.3389/fgene.2021.725259
- 8. Hagen L, Khattar D, Whitehead K, He H, Swarr DT, Suhrie K. Detection and impact of genetic disease
  in a level IV neonatal intensive care unit. *J Perinatol Off J Calif Perinat Assoc*. 2022;42(5):580-588.
  doi:10.1038/s41372-022-01338-0
- 548 9. The NICUSeq Study Group, Krantz ID, Medne L, et al. Effect of Whole-Genome Sequencing on the
  549 Clinical Management of Acutely III Infants With Suspected Genetic Disease: A Randomized Clinical
  550 Trial. JAMA Pediatr. 2021;175(12):1218. doi:10.1001/jamapediatrics.2021.3496
- 10. Australian Genomics Health Alliance Acute Care Flagship, Lunke S, Eggers S, et al. Feasibility of
  Ultra-Rapid Exome Sequencing in Critically III Infants and Children With Suspected Monogenic
  Conditions in the Australian Public Health Care System. JAMA. 2020;323(24):2503-2511.
  doi:10.1001/jama.2020.7671
- 11. Ceyhan-Birsoy O, Murry JB, Machini K, et al. Interpretation of Genomic Sequencing Results in
  Healthy and III Newborns: Results from the BabySeq Project. *Am J Hum Genet*. 2019;104(1):76-93.
  doi:10.1016/j.ajhg.2018.11.016
- Dimmock D, Caylor S, Waldman B, et al. Project Baby Bear: Rapid precision care incorporating
   rWGS in 5 California children's hospitals demonstrates improved clinical outcomes and reduced costs
   of care. Am J Hum Genet. 2021;108(7):1231-1238. doi:10.1016/j.ajhg.2021.05.008

561 13. Olde Keizer RACM, Marouane A, Kerstjens-Frederikse WS, et al. Rapid exome sequencing as a
562 first-tier test in neonates with suspected genetic disorder: results of a prospective multicenter clinical
563 utility study in the Netherlands. *Eur J Pediatr*. 2023;182(6):2683-2692. doi:10.1007/s00431-023564 04909-1

- McDermott H, Sherlaw-Sturrock C, Baptista J, Hartles-Spencer L, Naik S. Rapid exome
  sequencing in critically ill children impacts acute and long-term management of patients and their
  families: A retrospective regional evaluation. *Eur J Med Genet*. 2022;65(9):104571.
  doi:10.1016/j.ejmg.2022.104571
- 56915.Farnaes L, Hildreth A, Sweeney NM, et al. Rapid whole-genome sequencing decreases infant570morbidity and cost of hospitalization. NPJ Genomic Med. 2018;3:10. doi:10.1038/s41525-018-0049-4
- 571 16. Freed AS, Clowes Candadai SV, Sikes MC, et al. The Impact of Rapid Exome Sequencing on
  572 Medical Management of Critically III Children. *J Pediatr*. 2020;226:202-212.e1.
  573 doi:10.1016/j.jpeds.2020.06.020
- 574 17. Petrikin JE, Cakici JA, Clark MM, et al. The NSIGHT1-randomized controlled trial: rapid whole575 genome sequencing for accelerated etiologic diagnosis in critically ill infants. *Npj Genomic Med*.
  576 2018;3(1):6. doi:10.1038/s41525-018-0045-8
- Meng L, Pammi M, Saronwala A, et al. Use of Exome Sequencing for Infants in Intensive Care
   Units: Ascertainment of Severe Single-Gene Disorders and Effect on Medical Management. JAMA
   *Pediatr.* 2017;171(12):e173438. doi:10.1001/jamapediatrics.2017.3438
- French CE, Delon I, Dolling H, et al. Whole genome sequencing reveals that genetic conditions
  are frequent in intensively ill children. *Intensive Care Med*. 2019;45(5):627-636. doi:10.1007/s00134019-05552-x
- Scholz T, Blohm ME, Kortüm F, et al. Whole-Exome Sequencing in Critically III Neonates and
   Infants: Diagnostic Yield and Predictability of Monogenic Diagnosis. *Neonatology*. 2021;118(4):454 doi:10.1159/000516890
- 586 21. Maron JL, Kingsmore S, Gelb BD, et al. Rapid Whole-Genomic Sequencing and a Targeted
  587 Neonatal Gene Panel in Infants With a Suspected Genetic Disorder. *JAMA*. 2023;330(2):161-169.
  588 doi:10.1001/jama.2023.9350
- Wild KT, Miquel-Verges F, Rintoul NE, et al. Current Practices for Genetic Testing in Neonatal
   Extracorporeal Membrane Oxygenation: Findings from a National survey. *Perfusion*. 2024;39(1):116 123. doi:10.1177/02676591221130178
- 592 23. Callahan KP, Radack J, Wojcik MH, et al. Hospital-level variation in genetic testing in children's
  593 hospitals' neonatal intensive care units from 2016 to 2021. *Genet Med*. 2023;25(3):100357.
  594 doi:10.1016/j.gim.2022.12.004
- 595 24. Hays T, Hernan R, Disco M, et al. Implementation of Rapid Genome Sequencing for Critically III
  596 Infants With Complex Congenital Heart Disease. *Circ Genomic Precis Med*. 2023;16(5):415-420.
  597 doi:10.1161/CIRCGEN.122.004050

59825.Franck LS, Kriz RM, Rego S, Garman K, Hobbs C, Dimmock D. Implementing Rapid Whole-599Genome Sequencing in Critical Care: A Qualitative Study of Facilitators and Barriers to New600Technology Adoption. J Pediatr. 2021;237:237-243.e2. doi:10.1016/j.jpeds.2021.05.045

D'Gama AM, Del Rosario MC, Bresnahan MA, Yu TW, Wojcik MH, Agrawal PB. Integrating rapid
 exome sequencing into NICU clinical care after a pilot research study. *NPJ Genomic Med*.
 2022;7(1):51. doi:10.1038/s41525-022-00326-9

Leon RL, Levy PT, Hu J, et al. Practice variations for fetal and neonatal congenital heart disease
within the Children's Hospitals Neonatal Consortium. *Pediatr Res.* 2023;93(6):1728-1735.
doi:10.1038/s41390-022-02314-2

Wojcik MH, Callahan KP, Antoniou A, et al. Provision and availability of genomic medicine
services in Level IV neonatal intensive care units. *Genet Med Off J Am Coll Med Genet*.
2023;25(10):100926. doi:10.1016/j.gim.2023.100926

Elliott AM, du Souich C, Lehman A, et al. RAPIDOMICS: rapid genome-wide sequencing in a
neonatal intensive care unit-successes and challenges. *Eur J Pediatr*. 2019;178(8):1207-1218.
doi:10.1007/s00431-019-03399-4

Saunders CJ, Miller NA, Soden SE, et al. Rapid whole-genome sequencing for genetic disease
diagnosis in neonatal intensive care units. *Sci Transl Med*. 2012;4(154):154ra135.
doi:10.1126/scitranslmed.3004041

616 31. Clark MM, Hildreth A, Batalov S, et al. Diagnosis of genetic diseases in seriously ill children by
617 rapid whole-genome sequencing and automated phenotyping and interpretation. *Sci Transl Med.*618 2019;11(489):eaat6177. doi:10.1126/scitranslmed.aat6177

61932.Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-620exome sequencing. JAMA. 2014;312(18):1870-1879. doi:10.1001/jama.2014.14601

62133.Guo F, Liu R, Pan Y, et al. Evidence from 2100 index cases supports genome sequencing as a622first-tier genetic test. Genet Med. 2024;26(1):100995. doi:10.1016/j.gim.2023.100995

34. Willig LK, Petrikin JE, Smith LD, et al. Whole-genome sequencing for identification of Mendelian
disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings. *Lancet Respir Med.* 2015;3(5):377-387. doi:10.1016/S2213-2600(15)00139-3

- 62635.van Diemen CC, Kerstjens-Frederikse WS, Bergman KA, et al. Rapid Targeted Genomics in627Critically III Newborns. Pediatrics. 2017;140(4):e20162854. doi:10.1542/peds.2016-2854
- Stark Z, Lunke S, Brett GR, et al. Meeting the challenges of implementing rapid genomic testing
  in acute pediatric care. *Genet Med Off J Am Coll Med Genet*. 2018;20(12):1554-1563.
  doi:10.1038/gim.2018.37

631	37.	Mestek-Boukhibar L, Clement E, Jones WD, et al. Rapid Paediatric Sequencing (RaPS):
632	соі	nprehensive real-life workflow for rapid diagnosis of critically ill children. J Med Genet.
633	20	18;55(11):721-728. doi:10.1136/jmedgenet-2018-105396

Sanford EF, Clark MM, Farnaes L, et al. Rapid Whole Genome Sequencing Has Clinical Utility in
 Children in the PICU. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care
 Soc. 2019;20(11):1007-1020. doi:10.1097/PCC.00000000002056

- Gubbels CS, VanNoy GE, Madden JA, et al. Prospective, phenotype-driven selection of critically ill
   neonates for rapid exome sequencing is associated with high diagnostic yield. *Genet Med Off J Am Coll Med Genet*. 2020;22(4):736-744. doi:10.1038/s41436-019-0708-6
- Wu ET, Hwu WL, Chien YH, et al. Critical Trio Exome Benefits In-Time Decision-Making for
  Pediatric Patients With Severe Illnesses. *Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc.* 2019;20(11):1021-1026. doi:10.1097/PCC.00000000002068
- 64341.Wang H, Qian Y, Lu Y, et al. Clinical utility of 24-h rapid trio-exome sequencing for critically ill644infants. Npj Genomic Med. 2020;5(1):20. doi:10.1038/s41525-020-0129-0
- 645 42. Carey AS, Schacht JP, Umandap C, et al. Rapid exome sequencing in PICU patients with new646 onset metabolic or neurological disorders. *Pediatr Res*. 2020;88(5):761-768. doi:10.1038/s41390-020647 0858-x
- 648 43. Smith HS, Swint JM, Lalani SR, et al. Exome sequencing compared with standard genetic tests for
  649 critically ill infants with suspected genetic conditions. *Genet Med Off J Am Coll Med Genet*.
  650 2020;22(8):1303-1310. doi:10.1038/s41436-020-0798-1
- 651 44. Chung CCY, Leung GKC, Mak CCY, et al. Rapid whole-exome sequencing facilitates precision
   652 medicine in paediatric rare disease patients and reduces healthcare costs. *Lancet Reg Health West* 653 *Pac.* 2020;1:100001. doi:10.1016/j.lanwpc.2020.100001
- 65445.Powis Z, Farwell Hagman KD, Blanco K, et al. When moments matter: Finding answers with rapid655exome sequencing. *Mol Genet Genomic Med.* 2020;8(2):e1027. doi:10.1002/mgg3.1027
- 65646.Śmigiel R, Biela M, Szmyd K, et al. Rapid Whole-Exome Sequencing as a Diagnostic Tool in a657Neonatal/Pediatric Intensive Care Unit. J Clin Med. 2020;9(7):2220. doi:10.3390/jcm9072220
- 47. Maron JL, Kingsmore SF, Wigby K, et al. Novel Variant Findings and Challenges Associated With
  the Clinical Integration of Genomic Testing: An Interim Report of the Genomic Medicine for III
  Neonates and Infants (GEMINI) Study. JAMA Pediatr. 2021;175(5):e205906.
  doi:10.1001/jamapediatrics.2020.5906
- 48. Denommé-Pichon AS, Vitobello A, Olaso R, et al. Accelerated genome sequencing with
  controlled costs for infants in intensive care units: a feasibility study in a French hospital network. *Eur J Hum Genet EJHG*. 2022;30(5):567-576. doi:10.1038/s41431-021-00998-4
- 49. Halabi N, Ramaswamy S, El Naofal M, et al. Rapid whole genome sequencing of critically ill
  pediatric patients from genetically underrepresented populations. *Genome Med*. 2022;14(1):56.
  doi:10.1186/s13073-022-01061-7
- 50. Diaby V, Babcock A, Huang Y, et al. Real-world economic evaluation of prospective rapid wholegenome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in
  the United States. *Pharmacogenomics J.* 2022;22(4):223-229. doi:10.1038/s41397-022-00277-5

671 51. Wells CF, Boursier G, Yauy K, et al. Rapid exome sequencing in critically ill infants:

- 672 implementation in routine care from French regional hospital's perspective. *Eur J Hum Genet EJHG*.
  673 2022;30(9):1076-1082. doi:10.1038/s41431-022-01133-7
- 52. Bupp CP, Ames EG, Arenchild MK, et al. Breaking Barriers to Rapid Whole Genome Sequencing in Pediatrics: Michigan's Project Baby Deer. *Children*. 2023;10(1):106. doi:10.3390/children10010106
- 676 53. Pronman-Thompson L. Clinical utility of positive, negative and uncertain results of rapid whole
   677 genome sequencing for infants in an inpatient setting.
- 54. Lumaka A, Fasquelle C, Debray FG, et al. Rapid Whole Genome Sequencing Diagnoses and
  Guides Treatment in Critically III Children in Belgium in Less than 40 Hours. *Int J Mol Sci.*2023;24(4):4003. doi:10.3390/ijms24044003
- 55. Wojcik MH, Bresnahan M, Del Rosario MC, Ojeda MM, Kritzer A, Fraiman YS. Rare diseases,
  common barriers: disparities in pediatric clinical genetics outcomes. *Pediatr Res*. 2023;93(1):110-117.
  doi:10.1038/s41390-022-02240-3

56. Fraiman YS, Wojcik MH. The influence of social determinants of health on the genetic diagnostic
odyssey: who remains undiagnosed, why, and to what effect? *Pediatr Res.* 2021;89(2):295-300.
doi:10.1038/s41390-020-01151-5

57. Best S, Vidic N, An K, Collins F, White SM. A systematic review of geographical inequities for
 accessing clinical genomic and genetic services for non-cancer related rare disease. *Eur J Hum Genet EJHG*. 2022;30(6):645-652. doi:10.1038/s41431-021-01022-5

58. Edwards TL, Breeyear J, Piekos JA, Velez Edwards DR. Equity in Health: Consideration of Race
and Ethnicity in Precision Medicine. *Trends Genet*. 2020;36(11):807-809.
doi:10.1016/j.tig.2020.07.001

- 59. Khoury MJ, Bowen S, Dotson WD, et al. Health equity in the implementation of genomics and
  precision medicine: A public health imperative. *Genet Med Off J Am Coll Med Genet*.
  2022;24(8):1630-1639. doi:10.1016/j.gim.2022.04.009
- 69660.Ravi D, Iacob A, Profit J. Unequal care: Racial/ethnic disparities in neonatal intensive care697delivery. Semin Perinatol. 2021;45(4):151411. doi:10.1016/j.semperi.2021.151411
- 61. Wallace M, Crear-Perry J, Richardson L, Tarver M, Theall K. Separate and unequal: Structural
  racism and infant mortality in the US. *Health Place*. 2017;45:140-144.
  doi:10.1016/j.healthplace.2017.03.012
- Profit J, Gould JB, Bennett M, et al. Racial/Ethnic Disparity in NICU Quality of Care Delivery.
   *Pediatrics*. 2017;140(3):e20170918. doi:10.1542/peds.2017-0918
- Horbar JD, Edwards EM, Greenberg LT, et al. Variation in Performance of Neonatal Intensive
  Care Units in the United States. *JAMA Pediatr*. 2017;171(3):e164396.
  doi:10.1001/jamapediatrics.2016.4396

Howell EA, Janevic T, Hebert PL, Egorova NN, Balbierz A, Zeitlin J. Differences in Morbidity and
 Mortality Rates in Black, White, and Hispanic Very Preterm Infants Among New York City Hospitals.
 JAMA Pediatr. 2018;172(3):269-277. doi:10.1001/jamapediatrics.2017.4402

- Sigurdson K, Mitchell B, Liu J, et al. Racial/Ethnic Disparities in Neonatal Intensive Care: A
  Systematic Review. *Pediatrics*. 2019;144(2):e20183114. doi:10.1542/peds.2018-3114
- Glazer KB, Sofaer S, Balbierz A, Wang E, Howell EA. Perinatal care experiences among racially
   and ethnically diverse mothers whose infants required a NICU stay. J Perinatol Off J Calif Perinat
   Assoc. 2021;41(3):413-421. doi:10.1038/s41372-020-0721-2
- Borovetz HS, Kormos RL, Griffith BP, Hung TC. Clinical utilization of the artificial heart. *Crit Rev Biomed Eng*. 1989;17(2):179-201.
- 71668.R Core Team. R: A language and environment for statistical computing. https://www.R-717project.org/
- 718 69. DC Goodman, Little G, Harrison W, Moen A, Mowitz M, Ganduglia-Cazaban C. *The Dartmouth* 719 *Atlas of Neonatal Intensive Care*. Dartmouth Institute Health Policy Clinical Practice; 2019.
- 72070.Kingsmore SF, Cole FS. The Role of Genome Sequencing in Neonatal Intensive Care Units. Annu721Rev Genomics Hum Genet. 2022;23(1):427-448. doi:10.1146/annurev-genom-120921-103442
- 722
- 723
- 724
- 725
- 726
- 727
- 728
- ---
- 729
- 730
- 731
- 732
- 733
- 734
- /34
- 735

## 736 Figure legends:

737

# 738 Figure 1. STROBE diagram

739 SeqFirst-neo cohort ascertainment of interventional group (IG) and conventional care group

740 (CCG) depicted using a STROBE diagram.

741

## 742 Figure 2. Adjudication of variants reported in patients in the intervention cohort

743 Of the 126 participants, 85 had one or more potentially explanatory variants reported by

GeneDx based on the American College of Medical Geneics and Genomics (ACMG) guidelines

for clinical sequence interpretation (variant of uncertain significance [VUS], likely pathogenic

[LP], pathogenic [P]). We grouped these variants by the genes/regions in which they were

reported (i.e., single gene, cytogenetic event, mitochondrial event) and by the inferred

inheritance pattern(s) of the condition(s) they underlie (autosomal dominant [AD] or X-linked

[XL], autosomal recessive [AR], or unknown mode of inheritance [MOI] for genes that underlie

both AD and AR conditions. Variant(s) or event(s) and the MOI were then adjudicated together

to determine whether each combination was explanatory of clinical findings (either partly or

fully), unrelated to clinical findings and secondary, or of uncertain relationship to clinical findings

of each participant. Variants / events in each participant were counted separately so for

example the same genotype in two participants would be counted twice.

755

# 756 **Figure 3. Diagnostic yield in the intervention group**

757 Overall diagnostic yield stratified by test result category in the intervention group (IG) and the

conventional care group (CCG) at 90 days and one year post ascertainment.

# Figure 4. Diagnostic yield in the intervention group by phenotypic presentation and by racial construct

(A) Diagnostic yield in the intervention group (IG) stratified by phenotype presentation, parent or
provider assigned racial construct (PPARC) and test result category. Abbreviations: multiple
congenital anomalies, MCA; congenital heart defects, CHD. (B) Access to a PrGD / diagnostic
yield in the intervention group (IG), access to a PrGD in the conventional care group (CCG) and
the diagnostic yield in the conventional care group who received genetic testing (CCG-tested)
stratified by PPARC. Abbreviations: precise genetic diagnosis (PrGD). Asterisks denote
statistically significant differences between groups.

769

## 770 Figure 5. Impact of PPARC on prediction of precise genetic diagnosis in newborns

771 Prediction of precise genetic diagnosis (PrGD) status for non-white and non-Hispanic, white 772 infants in the intervention group (IG) as assessed by patterns of referral for a genetics consult 773 by their neonatologists. We defined successful prediction of PrGD status as requesting 774 consultation on a patient who was later found to have a PrGD and not requesting consultation 775 on a patient who was not found to have a PrGD. Neonatologists missed requesting a genetics 776 consult significantly more often (2.4-fold) for non-white infants who would eventually receive a 777 PrGD and also referred non-white infants for consults who were 0.17-fold less likely to go on to 778 receive a PrGD. This translates to higher precision (75%) and recall (86%) for predicting PrGD 779 status for non-Hispanic white infants than for non-white infants (55% vs. 68%, respectively).

780

# 781 Figure 6. Impact of a precise genetic diagnosis on changes in management

The impact of a precise genetic diagnosis on changes in management (COM) stratified by parent or provider assigned racial construct (PPARC). Management options are reflected in the text at the lower left, with blackened circles representing assessment by clinical team. Multiple options could be selected. The vertical black lines connecting blackened circles represent a

786	unique combination of COM options and all the unique COM combinations reported more than
787	once are shown. Bar plots above each set of responses indicate the number of families with
788	each COM combination stratified by PPARC. Abbreviations: anticipatory guidance (guidance),
789	genetic counseling (counseling), request for additional consults (consults), ordering additional
790	laboratory tests (labs), evaluation of other family members (cascade evaluation), ordering
791	additional imaging studies (imaging), addition of medications (meds), canceling laboratory tests,
792	imaging studies, or medications (cancel orders).
793	
794	
795	
796	
797	
798	
799	
800	
801	
802	
803	
804	
805	
806	
807	
808	
809	
810	
811	

# 812 Tables

## Table 1: Characteristics of Intervention Group (IG) and Conventional Care Groups (CCG)

814

	IG (n=126)	CCG (n=114)
Mean gestational age at birth (weeks)	36.5	36.5
Median gestational age at birth (weeks)	37.6	37.3
Mean age at admission (days)	10.6	5.5
Median age at admission (days)	2	1
Male	74 (58.7%)	56 (49.1%)
Female	52 (41.3%)	58 (50.9%)
Asian	23 (18.3%)	17 (14.9%)
Black	10 (7.9%)	12 (10.5%)
Hispanic	23 (18.3%)	20 (17.5%)
Native American	5 (4.0%)	3 (2.6%)
Non-white, multi-racial	13 (10.3%)	7 (6.1%)
Unknown	0 (0%)	7 (6.1%)
non-Hispanic white	52 (41.3%)	48 (42.1%)
Black+1P*	17 (13.5%)	17 (14.9%)
Total non-white	74 (58.7%)	59 (51.8%)
Multiple congenital anomalies	56 (44.4%)	44 (38.6%)
Isolated congenital anomaly	33 (26.2%)	33 (29.0%)
Abnormal lab value	10 (7.94%)	11 (9.65%)

<sup>815</sup> 

\*families with at least one parent who identified as Black categorized as Black+1P instead of

817 multi-racial

818

820	
821	
822	Table 2: Access to a PrGD among different PPARC groups at 90 days
823	

# PrGD at 90 days

p-values

PPARC groups	Intervention (n=126)	CCG (n=107*)	CCG any testing (n=46)	Intervention vs. CCG	Intervention vs. CCG any testing
Asian	12/23 (52.2%)	4/17 (23.5%)	4/8 (50%)	0.1043	0.4759
Black	8/10 (80%)	0/12 (0.0%)	0/4 (0%)	0.00001	0.015
Hispanic	8/23 (34.8%)	2/20 (10.0%)	2/10 (20%)	0.0764	0.6822
Native American	1/5 (20%)	0/3 (0.0%)	0/0 (0%)	1.0000	n/a
non-white, multi-racial	5/13 (38.5%)	0/7 (0.0%)	0/7 (0%)	0.1137	0.1137
non-Hispanic white	28/52 (53.8%)	5/48 (10.4%)	5/17 (10.4%)	<0.00001	0.0988
total	62/126 (49.2%)	11/107 (10.3%)	11/46 (23.9%)	<0.00001	0.0031
total non-white	34/74 (45.9%)	6/59 (10.2%)	6/29 (20.7%)	<0.00001	0.0241
Black+1P	11/17 (45.9%)	0/17 (0.0%)	0/8 (0%)	0.0001	0.0029

\*CCG cohort denominator for this analysis totals 107 because seven cases had unknown PPARC.

# 837

838

			Likely	partially	secondary	not
	total	explained	explained	explained	only	explained
MCA	56	18	8	4	3	23
MCA w/ CHD	28	10	4	2	1	11
MCA w/o CHD	28	8	4	2	2	12
Isolated congenital anomaly	33	4	7	0	2	20
abnormal lab test	10	6	1	0	0	3
hematological abnormality	2	2	0	0	0	0
seizures	9	3	2	0	1	3
single or multi-organ failure	6	1	1	0	0	4

839

840 Table 3: PrGD for Intervention Group by Categorical Admission Diagnosis

841

	strokes	3	0	0	0	0	3
	other	7	3	2	0	0	2
843							
844							
845							
846							
847							
848							
849							
850							
851							
852							

Figure 1



Figure 2





Figure 3









Figure 5



Figure 6



changes in management